Jild 3 № 2 (2026): Aprel - Iyun
73-84
2026-06-29
Ochiq kirish

Yurak-qon tomir kasalliklarida PRMT–ADMA–DDAH tizimi: oqsil arginin metillanishining endotelial disfunksiya va tomirlar remodellanishi bilan bogʻliqligi

Munisaxon Maxkamova
Nargiza Nurillaeva
https://doi.org/10.70626/cardiouz-2026-3-00090

Qabul qilingan: 2026-02-28

Nashr etilgan: 2026-06-29

PDF (inglizcha)
Crossmark Crossmark

Annotatsiya

Endotelial disfunksiya yurak-qon tomir kasalliklarining boshlanishi va rivojlanishi asosida yotuvchi muhim patofiziologik jarayonlardan biri bo‘lib, azot oksidi (NO) biologik mavjudligining pasayishi, oksidlovchi stress va yallig‘lanishning kuchayishi, vazokonstriksiya hamda qon tomir devorida protrombotik signalizatsiyaning faollashishi bilan tavsiflanadi. NO yo‘lining endogen regulyatorlari orasida azot oksidi sintazasining endogen ingibitori bo‘lgan assimetrik dimetilarginin (ADMA) metabolik stress bilan tomir disfunksiyasini bog‘lovchi muhim molekulyar bo‘g‘in sifatida qaralmoqda. Biroq qonda aylanib yuruvchi ADMA oqsil arginin metiltransferazalari (PRMTlar), dimetilarginin dimetilaminohidrolazalari (DDAHlar) hamda metillangan arginin hosilalarini metabolizmga uchratuvchi muqobil yo‘llarni o‘z ichiga olgan kengroq regulyator tarmoqning faqat bir qismidir. Ushbu sharhda PRMT–ADMA–DDAH–eNOS/NO o‘qining molekulyar tuzilishi hamda uning ateroskleroz, koronar arteriya kasalligi, arterial gipertenziya, yurak yetishmovchiligi, kardiometabolik buzilishlar, surunkali buyrak kasalligi va metabolik disfunksiya bilan bog‘liq steatotik jigar kasalligi rivojlanishidagi o‘rni ko‘rib chiqiladi. Shuningdek, PRMT faolligi, ADMA metabolizmi, DDAH1 va AGXT2 hamda NO biologik mavjudligiga ta’sir ko‘rsatishga qaratilgan terapevtik yondashuvlarning imkoniyatlari va cheklovlari muhokama qilinadi. Ushbu regulyator tarmoqni chuqurroq tushunish qoldiq yurak-qon tomir xavfining endotelial fenotiplarini aniqlash va yurak-qon tomir kasalliklarini oldini olish hamda davolashning yanada individuallashtirilgan strategiyalarini ishlab chiqish uchun mexanistik asos yaratishi mumkin.

Kalit so‘zlar

Adabiyotlar ro'yxati

  1. Pope, A. J., Karuppiah, K., & Cardounel, A. J. (2009). Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production. Pharmacological research, 60(6), 461–465. https://doi.org/10.1016/j.phrs.2009.07.016

  2. Zoccali C, Bode-Böger SM, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358(9299):2113–2117. doi: https://doi.org/10.1016/S0140-6736(01)07217-8. PMID: 11784625.

  3. Reddy ST, Wadleigh DJ, Herschman HR. Transcriptional regulation of the cyclooxygenase-2 gene in activated mast cells. J Biol Chem. 2000;275(5):3107–3113. doi: https://doi.org/10.1074/jbc.275.5.3107.

  4. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23(8):1455–1459. doi: https://doi.org/10.1161/01.ATV.0000081742.92006.59.

  5. Relationship between metabolical associated steatotic liver disease and ischemic heart disease: clinical aspects of comorbidity (M. . Makhkamova & N. . Nurillayeva, Trans.). (2024). CARDIOLOGY OF UZBEKISTAN, 1(4), 221-227. https://doi.org/10.70626/cardiouz-2024-1-00025

  6. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99(24):3092–3095. doi: https://doi.org/10.1161/01.CIR.99.24.3092. PMID: 10377069.

  7. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O’Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, Smith C, Wojciak-Stothard B, Rudiger A, Stidwill R, McDonald NQ, Vallance P. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med. 2007;13(2):198–203. doi: https://doi.org/10.1038/nm1543.

  8. Konrad L, Scheiber JA, Bergmann M, Eickelberg O, Hofmann R. Identification of a new human Smad6 splice variant. Andrologia. 2008;40(6):358–363. doi: https://doi.org/10.1111/j.1439-0272.2008.00869.x.

  9. Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, Leonelli L, Sonbuchner LS, McDonald CH, Cook RG, Dou Y, Roeder RG, Clarke S, Stallcup MR, Allis CD, Coonrod SA. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science. 2004;306(5694):279–283. doi: https://doi.org/10.1126/science.1101400.

  10. Nurillaeva N.M.; Makhkamova M.M.; Srojidinova N.Z. Role of metabolic disorders in the formation of asymmetric dimethylarginine levels in patients with ischemic heart disease. International Journal of Heart and Vascular Diseases. 2025;13(47):13–20. (In Russian)

  11. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104(21):2569–2575. PMID: 11714652.

  12. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperho-mocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000;20(6):1557–1564. doi: https://doi.org/10.1161/01.atv.20.6.1557.

  13. Zhussupbekova, Lazzat, Munisakhon Makhkamova, Nargiza Nurillaeva, Dinara Nurkina, Farrukh Yul-dashov, and Doston Ubaydullayev. 2026. "Asymmetric Dimethylarginine as an Integrative Biomarker of En¬dothelial, Cardiometabolic and Hepatic Dysfunction in Stable Coronary Artery Disease" Biomedicines 14, no. 9: 1927. https://doi.org/10.3390/biomedicines14091927.

  14. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arte-rioscler Thromb Vasc Biol. 2003;23(8):1455–1459. doi: https://doi.org/10.1161/01.ATV.0000081742.9 2006.59. PMID: 12805079.

  15. Makhkamova M.M.; Nurillaeva N.M. Study of the frequency of compliance with metabolic dysfunction criteria in patients with ischemic heart disease and concomitant hematological profile disorders. Journal of Humanities and Natural Sciences. 2024;1(15):166–168. Available online: https://journals.tnmu.uz/ index.php/gtfj/article/view/732. (In Russian)

  16. Jacobi J, Sydow K, von Degenfeld G, Zhang Y, Dayoub H, Wang B, Patterson AJ, Kimoto M, Blau HM, Cooke JP. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation. 2005;111(11):1431–1438. doi: https://doi.org/10.1161/01.CIR.0000158487.80483.09.

  17. Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl. 2003;4(4):41–51. doi: https://doi.org/10.1016/S1567-5688(03)00033-3. PMID: 14664902.

  18. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004;24:1023–1030. doi: https://doi.org/10.1161/01.ATV.0000128897.54893.26.

  19. Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor. J Nutr. 2004. PMID: 15465797.

  20. Tanaka M, Sydow K, Gunawan F, et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation. 2005;112(11):1549–1556. PMID: 16144995.

  21. Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular home-ostasis. Nat Med. 2007;13(2):198–203. doi: https://doi.org/10.1038/nm1543. PMID: 17273169.

  22. Meinitzer A, Seelhorst U, Wellnitz B, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem. 2007;53(2):273–283. doi: https://doi.org/10.1373/ clinchem.2006.076711. PMID: 17185364.

  23. Morales Y, Nitzel DV, Price OM, et al. Redox control of protein arginine methyltransferase 1 (PRMT1) activity. J Biol Chem. 2015;290(24):14915–14926. doi: https://doi.org/10.1074/jbc.M115.651380. PMID: 25911106.

  24. Hu X, Atzler D, Xu X, et al. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol. 2011;31:1540–1546. PMID: 21493890.

  25. Kopaliani I, Jarzebska N, Billoff S, et al. Overexpression of dimethylarginine dimethylaminohydrolase 1 protects from angiotensin II-induced cardiac hypertrophy and vascular remodeling. Am J Physiol Heart Circ Physiol. 2021;321(5):H825–H838. doi: https://doi.org/10.1152/ajpheart.00064.2021. PMID: 34533401.

  26. Ragavan VN, Nair PC, Jarzebska N, et al. A multicentric consortium study demonstrates that dimethy-larginine dimethylaminohydrolase 2 is not a dimethylarginine dimethylaminohydrolase. Nat Commun. 2023;14:3392. doi: https://doi.org/10.1038/s41467-023-38467-9. PMID: 37296100.

  27. Nair PC, et al. Redefining the biological and pathophysiological role of dimethylarginine dimethylamino-hydrolase 2. Trends Mol Med. 2024;30(6):552–561. doi: https://doi.org/10.1016/j.molmed.2024.03.001. PMID: 38553332.

  28. Wu Y, Qin X, Xiang M, Deng J. PRMT1 upregulates SIRT6 by enhancing arginine methylation of E2F7 to inhibit vascular smooth muscle cell senescence in aortic dissection. FASEB J. 2025;39(9):e70579. doi: https://doi.org/10.1096/fj.202403269R. PMID: 40298071.

  29. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GSJ, Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999;343(Pt 1):209–214. doi: https://doi.org/10.1042/bj3 430209. PMID: 10493931.

  30. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98(18):1842–1847. doi: https://doi.org/10.1161/01.CIR.98.18.1842. PMID: 9799202.

  31. Stühlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287(11):1420–1426. doi: https://doi.org/10.1001/jama.287.11.1420. PMID: 11903029.

  32. Suda O, Tsutsui M, Morishita T, et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol. 2004;24(9):1682–1688. doi: https://doi.org/10.1161/01.ATV.0000 136656.26019.6E. PMID: 15217805.

  33. Takiuchi S, Fujii H, Kamide K, et al. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens. 2004;17(9):802–808. doi: https://doi.org/10.1016/j.amjhyper.2004.05.005. PMID: 15363823.

  34. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005;46(3):518–523. doi: https://doi.org/10.1 016/j.jacc.2005.04.040. PMID: 16053968.

  35. Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol. 2005;46(9):1693–1701. doi: https://doi.org/10.1016/j.jacc.2005.04.066. PMID: 16256870.

  36. Chen Y, Li Y, Zhang P, Traverse JH, Hou M, Xu X, et al. Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts. Am J Physiol Heart Circ Physiol. 2005;289(5):H2212–H2219. doi: https://doi.org/10.1152/ajpheart.00224.2005. PMID: 16024577.

  37. Dückelmann C, Mittermayer F, Haider DG, Altenberger J, Eichinger J, Wolzt M. Asymmetric dimethy-larginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol. 2007;27(9):2037–2042. doi: https://doi.org/10.1161/ATVBAHA.107.147595. PMID: 17569878.

  38. Antoniades C, Demosthenous M, Tousoulis D, et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension. 2011;58(1):93–98. doi: https://doi.org/10.1161/HYPERTENSIONAHA.110.168245. PMID: 21518967.

  39. Wolf C, Lorenzen JM, Stein S, et al. Urinary asymmetric dimethylarginine (ADMA) is a predictor of mortality risk in patients with coronary artery disease. Int J Cardiol. 2012;156(3):289–294. doi: https://doi.org/10.1016/j.ijcard.2010.11.003. PMID: 21159392.

  40. Raj V, Natarajan S, Marimuthu C, et al. Cholecalciferol and metformin protect against lipopolysaccharide-induced endothelial dysfunction and senescence by modulating sirtuin-1 and protein arginine methyltransferase-1. Eur J Pharmacol. 2021;912:174531. doi: https://doi.org/10.1016/j.ejphar. 2021.174531. PMID: 34710370.

  41. Papageorgiou N, Theofilis P, Oikonomou E, Lazaros G, Sagris M, Tousoulis D. Asymmetric dimethy-larginine as a biomarker in coronary artery disease. Curr Top Med Chem. 2023;23(6):470–480. doi: https://doi.org/10.2174/1568026623666221213085917. PMID: 36515020.

  42. Hanson Ng YY, Dora KA, Lemmey HAL, Garland CJ, et al. Asymmetric dimethylarginine enables depolar-izing spikes and vasospasm in mesenteric and coronary resistance arteries. Hypertension. 2024;81(4):764–775. doi: https://doi.org/10.1161/HYPERTENSIONAHA.123.22454. PMID: 38226470.

  43. Tang JQ, Wang YK, Shen Q, Zhou XJ, Wang WZ, Tan X. The PRMT-mediated arginine methylation: From molecular mechanisms to therapeutic targets in cardiovascular diseases. Life Sci. 2026;385:124140. doi: https://doi.org/10.1016/j.lfs.2025.124140. PMID: 41352708.

Mualliflar haqida

Munisaxon Maxkamova
md_munisakhon@mail.ru
Toshkent Tibbiyot Akademiyasi
https://orcid.org/0000-0002-2658-6148 (avtorizatsiyalanmagan)
Nargiza Nurillaeva
nargizanur@yandex.ru
Toshkent davlat tibbiyot universiteti

Litsenziya

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Qanday iqtibos keltirish kerak

Yurak-qon tomir kasalliklarida PRMT–ADMA–DDAH tizimi: oqsil arginin metillanishining endotelial disfunksiya va tomirlar remodellanishi bilan bogʻliqligi (M. Maxkamova & N. Nurillaeva, Trans.). (2026). O’ZBEKISTON KARDIOLOGIYASI, 3(2), 73-84. https://doi.org/10.70626/cardiouz-2026-3-00090
Crossref
Scopus
Google Scholar
Europe PMC

Ushbu muallif(lar)ning eng koʻp oʻqilgan maqolalari

O'xshash maqolalar

Siz ham ushbu maqola uchun {$ advancedSearchLink} olishingiz mumkin.

ISSN 3060-4850 (Print)